Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series

Table 10 Effects of medical cannabis on fibromyalgia syndrome at 1, 3, and 12 months

	Prior MC	With MC	P	Prior MC	With MC	P	Prior MC	With MC	P
	1 month, 30 patients			3 months, 18 patients			12 months, 12 patients
Widespread pain index (WPI)
Median	14.5	12	<0.01	15	7	<0.01	15	8	>0.01
IQR	6.25	10.5		7.25	15.5		7.75	14.25
Mean	14.4	10.9		15	7		15	8
± SD	3.9	6.3		4.2	7.1		4.8	7
Severity score (SyS)
Median	11	9	<0.01	11	7	<0.01	10.5	6.5	<0.01
IQR	1.25	4		1.5	4		2	6.25
Mean	11	9		11	7		10.5	6.5
± SD	1.3	2.9		1.3	3.2		1.3	3.3

MC medical cannabis, IQR interquartile range, ± plus/minus, SD standard deviation. Fibromyalgia syndrome was measured with Widespread Pain Index (WPI) and with Severity Score (SyS). Wilcoxon signed-rank test was used to evaluate differences between time points

ISSN: 2522-5782